JPMorgan Chase & Co. Reiterates “Buy” Rating for Marina Biotech (MRNA)

Marina Biotech (OTCMKTS:MRNA)‘s stock had its “buy” rating restated by research analysts at JPMorgan Chase & Co. in a research report issued on Thursday.

Several other research firms also recently commented on MRNA. Morgan Stanley initiated coverage on Marina Biotech in a research note on Wednesday, January 2nd. They set an “overweight” rating and a $29.00 price objective for the company. Goldman Sachs Group initiated coverage on Marina Biotech in a research note on Wednesday, January 2nd. They set a “buy” rating and a $25.00 price objective for the company. Barclays initiated coverage on Marina Biotech in a research note on Wednesday, January 2nd. They set an “overweight” rating and a $20.00 price objective for the company. Needham & Company LLC initiated coverage on Marina Biotech in a research note on Wednesday, January 2nd. They set a “buy” rating and a $28.00 price objective for the company. Finally, Piper Jaffray Companies initiated coverage on Marina Biotech in a research note on Wednesday, January 2nd. They set an “overweight” rating and a $24.00 price objective for the company. Eight equities research analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and a consensus target price of $24.38.

MRNA opened at $17.00 on Thursday. Marina Biotech has a 52 week low of $13.03 and a 52 week high of $22.75.

About Marina Biotech

Marina Biotech, Inc, a biopharmaceutical company, engages in the development and commercialization of proprietary drug therapeutics primarily for hypertension, arthritis, pain, and oncology in the United States, Europe, and internationally. The company offers Prestalia, a single-pill fixed dose combination (FDC) of perindopril argenine, an angiotensin-converting-enzyme inhibitor; and amlodipine besylate, a calcium channel blocker for the treatment of hypertension.

Featured Story: What are the Different Types of Leveraged Buyouts?

Analyst Recommendations for Marina Biotech (OTCMKTS:MRNA)

Receive News & Ratings for Marina Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marina Biotech and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply